You are viewing the site in preview mode
Skip to main content
|
Author, reference (publication year)
|
Study design
|
Recruitment period
|
Number of patients
|
Median age
|
Sex (M/F)
|
Type
|
Conditioning regimen
|
GVHD prophylaxis
|
Interval from diagnosis to treatment (M)
|
Neutrophil recovery (d)
|
Platelet engraftment
|
MSCs originals
|
NOS score
|
|---|
|
Wang Z-K [31] (2019)
|
Single-arm study
|
January 2014-December 2016
|
35
|
11.5 (3–18)
|
18/17
|
SAA/VSAA (19/16)
|
Busulfan (Bu) + cyclophosphamide (Cy) + antithymocyte globulin (ATG)
|
CsA + MMF + MTX
|
NA
|
14 (10–22)
|
18 (9–36)
|
BM
|
6
|
|
Yue C [32] (2018)
|
Cases
|
January 2014-January 2017
|
6
|
23 (15–31)
|
3/3
|
VSAA (6)
|
Busulfan (Bu) + cyclophosphamide (Cy) + antithymocyte globulin (rATG)
|
CsA + MMF + MTX
|
2 (1–3.5)
|
13 (9–19)
|
15.5 (10–23)
|
BM
|
5
|
|
Liu Z [33] (2017)
|
Single-arm study
|
March 2013-August 2015
|
44
|
24 (8–47)
|
29/15
|
SAA/VSAA (31/13)
|
Busulfan (Bu) + cyclophosphamide (Cy) + antithymocyte globulin (ATG)
|
CsA + MMF + MTX
|
31.2 (1–249)
|
12 (8–21)
|
19 (8–154)
|
BM
|
6
|
|
Xu L [34] (2018)
|
Single-arm study
|
June 2010-August 2013
|
24
|
16.5 (5–55)
|
14/10
|
SAA (24)
|
Cyclophosphamide (Cy) + antithymocyte globulin (rATG) + FLU or
|
CsA + ATG+ CD25Ab + mycophenolate material
|
NA
|
11 (10–25)
|
13 (10–25)
|
UC
|
6
|
|
Wu Y [35] (2017)
|
Single-arm study
|
January 2011-June 2016
|
77
|
9 (1–46)
|
39/38
|
SAAVSAA/SAA and PNH (72/5)
|
Cyclophosphamide (Cy) + antithymocyte globulin (ATG) + FLU ± busulfan
|
CsA + MMF + MTX + CD25Ab
|
7 (2–182)
|
12(8–21)
|
14 (9–30)
|
UC
|
5
|
|
Li XH [36] (2014)
|
Single-arm study
|
October 2006-October 2012
|
17
|
19 (4–29)
|
10/7
|
SAA/VSAA (8/9)
|
Cyclophosphamide (Cy) + antithymocyte globulin (ATG) + FLU
|
CsA + MMF + CD25Ab
|
3 (1–5)
|
12 (11–21)
|
14 (11–75)
|
UC
|
6
|
|
Wu Y [37] (2014)
|
Single-arm study
|
January 2007-June 2013
|
21
|
18 (4–31)
|
11/10
|
SAA/VSAA/SAA and PNH (7/12/2)
|
Cyclophosphamide (Cy) + antithymocyte globulin (rATG) + FLU or
|
CsA + MMF + CD25Ab + rATG
|
6 (1–128)
|
12 (8–21)
|
14(10–23)
|
UC
|
6
|
|
Wang Z [38] (2014)
|
Single-arm study
|
March 2010-April 2013
|
17
|
10 (4–19)
|
6/11
|
SAA/VSAA/2 HSCT (11/5/1)
|
BU + fludarabine + CY + ATG
|
CsA + MMF + MTX + CD25Ab
|
12 (1–44)
|
16 (9–25)
|
22 (9–95)
|
UC
|
6
|
- Abbreviations: SAA severe aplastic anemia, VSAA very severe aplastic anemia, ATG antithymoglobulin, CsA cyclosporin A, MSCs mesenchymal stem cells, haplo-HSCT haplo-identical hematopoietic stem cell transplantation, BU busulfan, Cy cyclophosphamide, MMF mycophenolate mofetil, FLU fludarabine, MTX methotrexate, GVHD graft-versus-host disease
